Sab biotherapeutics presents positive ind-enabling glp toxicology study for sab-142, a novel immunotherapeutic for type 1 diabetes at focis 2023

Sab highlights results from glp toxicology study confirming sab-142's mechanism of action at the 23rd federation of clinical immunology societies (focis)

SABS Ratings Summary

SABS Quant Ranking